First Experimental Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic Dengue Antibodies

English version České info

Dengue (DEN) is an arthropod-transmitted viral disease which affects approximately 390 million individuals in the tropical and subtropical world annually. DEN clinical manifestations range from mild febrile illness (dengue fever) to life-threatening dengue hemorrhagic/dengue shock syndrome (DHF/DSS). Epidemiological observations indicate that infants born to dengue immune mothers are at greater risk to develop the severe form of the disease (DHF/DSS) upon infection with any serotype of dengue virus (DENV). It was proposed that the presence of maternally acquired DENV specific antibodies cross react but fail to neutralize DENV particles, resulting in higher viremia that correlates with increased disease severity. Direct experimental evidence supporting this antibody-dependent enhancement (ADE) hypothesis has been missing. Furthermore, a recent epidemiological report has challenged the influence of maternally acquired antibodies in disease outcome. Here, we have developed a mouse model of ADE where DENV2-infected mice born to DENV1 immune mothers displayed enhanced disease severity compared to DENV2-infected mice born to dengue naïve mothers. This is a long-overdue direct experimental evidence of the role of maternally acquired antibodies in dengue disease outcome. It provides a unique opportunity to dissect the mechanisms involved in this phenomenon.

Vyšlo v časopise: First Experimental Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic Dengue Antibodies. PLoS Pathog 10(4): e32767. doi:10.1371/journal.ppat.1004031
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004031

Souhrn

Zdroje

1. GuzmanMG, HalsteadSB, ArtsobH, BuchyP, FarrarJ, et al. (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8: S7–16.

2. HalsteadSB (2007) Dengue. Lancet 370 : 1644–1652.

3. WrightWF, PrittBS (2012) Update: The diagnosis and management of dengue virus infection in North America. Diagn Microbiol Infect Dis 73 : 215–220.

4. BhattS, GethingPW, BradyOJ, MessinaJP, FarlowAW, et al. (2013) The global distribution and burden of dengue. Nature 496(7446): 504–7.

5. World Health Organization (2009). Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. WHO/HTM/NTD/DEN/2009.1

6. ChambersTJ, HahnCS, GallerR, RiceCM (1990) Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44 : 649–688.

7. SimmonsCP, FarrarJJ, NguyenV, WillsB (2012) Dengue. N Engl J Med 366 : 1423–1432.

8. WHO (1997). Dengue hemorrhagic fever: diagnosis, treatment, prevention and control. 2nd edn. WHO, Geneva.

9. EdelmanR, HombachJ (2008) “Guidelines for the clinical evaluation of dengue vaccines in endemic areas”: summary of a World Health Organization Technical Consultation. Vaccine 26 : 4113–4119.

10. HalsteadSB (2012) Controversies in dengue pathogenesis. Paediatr Int Child Health 32 Suppl 1 : 5–9.

11. ZompiS, HarrisE (2012) Animal models of dengue virus infection. Viruses 4 : 62–82.

12. GuzmanMG, AlvarezM, HalsteadSB (2013) Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol doi 10.1007s0070501316453/s00705-013-1645-3

13. HalsteadSB (1970) Observations related to pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 42 : 350–362.

14. HalsteadSB, SimasthienP (1970) Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host. Yale J Biol Med 42 : 276–292.

15. HalsteadSB (1990) Global epidemiology of dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health 21 : 636–641.

16. RothmanAL (2011) Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11 : 532–543.

17. BoonnakK, SlikeBM, DonofrioGC, MarovichMA (2013) Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J Immunol 190(11): 5659–5665.

18. FlipseJ, WilschutJ, SmitJM (2013) Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic 14(1): 25–35.

19. ChenRF, YehWT, YangMY, YangKD (2001) A model of the real-time correlation of viral titers with immune reactions in antibody-dependent enhancement of dengue-2 infections. FEMS Immunol Med Microbiol 30 : 1–7.

20. LittauaR, KuraneI, EnnisFA (1990) Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144 : 3183–3186.

21. MorensDM, LarsenLK, HalsteadSB (1987) Study of the distribution of antibody-dependent enhancement determinants on dengue 2 isolates using dengue 2-derived monoclonal antibodies. J Med Virol 22 : 163–167.

22. MoiML, TakasakiT, SaijoM, KuraneI (2013) Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection. Trans R Soc Trop Med Hyg 107(1): 51–8.

23. GoncalvezAP, EngleRE, St ClaireM, PurcellRH, LaiCJ (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104 : 9422–9427.

24. BalsitisSJ, WilliamsKL, LachicaR, FloresD, KyleJL, et al. (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790.

25. ZellwegerRM, PrestwoodTR, ShrestaS (2010) Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7 : 128–139.

26. KliksSC, NimmanityaS, NisalakA, BurkeDS (1988) Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38 : 411–419.

27. SimmonsCP, ChauTN, ThuyTT, TuanNM, HoangDM, et al. (2007) Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 196(3): 416–24.

28. ChauTN, HieuNT, AndersKL, WolbersM, Lien leB, et al. (2009) Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis 200(12): 1893–900.

29. DuangchindaT, DejnirattisaiW, VasanawathanaS, LimpitikulW, TangthawornchaikulN, et al. (2010) Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 107(39): 16922–7.

30. ChauTN, QuyenNT, ThuyTT, TuanNM, HoangDM, et al. (2008) Dengue in Vietnamese infants; results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 198(4): 516–24.

31. HalsteadSB, LanNT, MyintTT, ShweTN, NisalakA, et al. (2002) Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis 8(12): 1474–9.

32. LibratyDH, AcostaLP, TalloV, Segubre-MercadoE, BautistaA, et al. (2009) A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 6(10): e1000171.

33. GrantD, TanGK, QingM, NgJK, YipA, et al. (2011) A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis. J Virol 85 : 7775–7787.

34. SchreiberMJ, HolmesEC, OngSH, SohHS, LiuW, et al. (2009) Genomic epidemiology of a dengue virus epidemic in urban Singapore. J Virol 83 : 4163–4173.

35. TanGK, NgJK, TrastiSL, SchulW, YipG, et al. (2010) A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 4: e672.

36. TanGK, NgJK, LimAH, YeoKP, AngeliV, et al. (2011) Subcutaneous infection with non-mouse adapted Dengue virus D2Y98P strain induces systemic vascular leakage in AG129 mice. Ann Acad Med Singapore 40 : 523–532.

37. ShrestaS, ShararKL, PrigozhinDM, BeattyPR, HarrisE (2006) Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80 : 10208–10217.

38. ChanKR, ZhangSL, TanHC, ChanYK, ChowA, et al. (2011) Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A 108 : 12479–12484.

39. VaughnDW, GreenS, KalayanaroojS, InnisBL, NimmannityaS, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181 : 2–9.

40. LibratyDH, EndyTP, HoungHS, GreenS, KalayanaroojS, et al. (2002) Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 185(9): 1213–21.

41. BasuA, ChaturvediUC (2008) Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol Med Microbiol 53 : 287–299.

42. SrikiatkhachornA (2009) Plasma leakage in dengue haemorrhagic fever. Thromb Haemost 102 : 1042–1049.

43. HoberD, PoliL, RoblinB, GestasP, ChungueE, et al. (1993) Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 48 : 324–331.

44. GreenS, VaughnDW, KalayanaroojS, NimmannityaS, SuntayakornS, et al. (1999) Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 179 : 755–762.

45. MalavigeGN, HuangLC, SalimiM, GomesL, JayaratneSD, et al. (2012) Cellular and cytokine correlates of severe dengue infection. PLOS one 7(11): e50387.

46. AtrasheuskayaA, PetzelbauerP, FredekingTM, IgnatyevG (2003) Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol 35 : 33–42.

47. Puerta-GuardoH, SandinoAR, González-MariscalL, RosalesVH, Ayala-DávilaJ, et al. (2013) The cytokine response of U937-derived macrophages infected through antibody-dependent enhancement of dengue virus disrupts cell apical-junction complexes and increases vascular permeability. J Virol 87(13): 7486–501.

48. LiuP, WodaM, EnnisFA, LibratyDH (2009) Dengue virus infection differentially regulates endothelial barrier function over time through type I interferon effects. J Infect Dis 200(2): 191–201.

49. HasselquistD, NilssonJA (2009) Maternal transfer of antibodies in vertebrates: trans-generational effects on offspring immunity. Philos Trans R Soc Lond B Biol Sci 364(1513): 51–60.

50. JonesM, DavidsonA, HibbertL, GruenwaldP, SchlaakJ, et al. (2005) Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol 79 : 5414–5420.

51. Munoz-JordanJL, Sanchez-BurgosGG, Laurent-RolleM, Garcia-SastreA (2003) Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A 100 : 14333–14338.

52. YoungDF, ChatziandreouN, HeB, GoodbournS, LambRA, et al. (2001) Single amino acid substitution in the V protein of simian virus 5 differentiates its ability to block interferon signaling in human and murine cells. J Virol 75 : 3363–3370.

53. JohnsonAJ, RoehrigJT (1999) New mouse model for dengue virus vaccine testing. J Virol 73 : 783–786.

54. OrozcoS, SchmidMA, ParameswaranP, LachicaR, HennMR, et al. (2012) Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol 93(Pt 10): 2152–7.

55. van PanhuisWG, LuxemburgerC, PengsaaK, LimkittikulK, SabchareonA, et al. (2011) Decay and persistence of maternal dengue antibodies among infants in Bangkok. Am J Trop Med Hyg 85 : 355–362.

56. FoxA, LeNM, SimmonsCP, WolbersM, WertheimHF, et al. (2011) Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. PLoS Negl Trop Dis 5(3): e967.

57. PiersonTC, DiamondMS (2008) Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 10: e12.

58. WhiteheadSS, BlaneyJE, DurbinAP, MurphyBR (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5 : 518–528.

59. HalsteadSB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60 : 421–467.

60. MorrisonJ, AguirreS, Fernandez-SesmaA (2012) Innate immunity evasion by Dengue virus. Viruses 4 : 397–413.

61. PrestwoodTR, PrigozhinDM, ShararKL, ZellwegerRM, ShrestaS (2008) A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J Virol 82(17): 8411–21.

62. LinCF, WanSW, ChengHJ, LeiHY, LinYS (2006) Autoimmune pathogenesis in dengue virus infection. Viral Immunol 19 : 127–132.

63. VenturaAK, EhrenkranzNJ, RosenthalD (1975) Placenta passage of antibodies to dengue virus in persons living in a region of hyperendemic dengue virus infection. J Infect Dis 131: S62–68.

64. WatanaveeradejV, EndyTP, SamakosesR, KerdpanichA, SimasathienS, et al. (2003) Transplacentally transferred maternal-infant antibodies to dengue virus. Am J Trop Med Hyg 69 : 123–128.